143 related articles for article (PubMed ID: 37888582)
21. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
22. Dupilumab Improved Alopecia Areata in a Patient with Atopic Dermatitis: A Case Report.
Uchida H; Kamata M; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Acta Derm Venereol; 2019 Jun; 99(7):675-676. PubMed ID: 30938821
[No Abstract] [Full Text] [Related]
23. Effectiveness of dupilumab for chronic prurigo in elderly patients with atopic dermatitis.
Mitsuyama S; Higuchi T
An Bras Dermatol; 2023; 98(1):86-89. PubMed ID: 36376117
[No Abstract] [Full Text] [Related]
24. Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review.
Hendricks AJ; Yosipovitch G; Shi VY
J Dermatolog Treat; 2021 Feb; 32(1):19-28. PubMed ID: 31693426
[No Abstract] [Full Text] [Related]
25. Severe eczema in Wiskott-Aldrich syndrome-related disorder successfully treated with dupilumab.
Alzahrani F; Miller HK; Sacco K; Dupuy E
Pediatr Dermatol; 2024; 41(1):143-144. PubMed ID: 37469225
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
27. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy.
Ferrucci S; Tavecchio S; Berti E; Angileri L
J Dermatolog Treat; 2021 Jun; 32(4):453-454. PubMed ID: 31442084
[TBL] [Abstract][Full Text] [Related]
28. Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab.
Cho MK; Shin JU; Kim DH; Lee HJ
Clin Exp Dermatol; 2022 Dec; 47(12):2303-2305. PubMed ID: 36006169
[TBL] [Abstract][Full Text] [Related]
29. CARD11 dominant negative mutation leads to altered human Natural Killer cell homeostasis.
Baronio M; Gazzurelli L; Rezzola S; Rossi S; Tessarin G; Marinoni M; Salpietro A; Fiore M; Moratto D; Chiarini M; Badolato R; Parolini S; Tabellini G; Lougaris V
Immunobiology; 2023 May; 228(3):152381. PubMed ID: 37086690
[TBL] [Abstract][Full Text] [Related]
30. Management of Atopy with Dupilumab and Omalizumab in CADINS Disease.
Diaz-Cabrera NM; Bauman BM; Iro MA; Dabbah-Krancher G; Molho-Pessach V; Zlotogorski A; Shamriz O; Dinur-Schejter Y; Sharon TD; Stepensky P; Tal Y; Eisenstein EM; Pietzsch L; Schuetz C; Abreu D; Coughlin CC; Cooper MA; Milner JD; Williams A; Armoni-Weiss G; Snow AL; Leiding JW
J Clin Immunol; 2024 Jan; 44(2):48. PubMed ID: 38231347
[TBL] [Abstract][Full Text] [Related]
31. Dupilumab for prurigo nodularis: Case series and review of the literature.
Holm JG; Agner T; Sand C; Thomsen SF
Dermatol Ther; 2020 Mar; 33(2):e13222. PubMed ID: 31917498
[TBL] [Abstract][Full Text] [Related]
32. DOK3 promotes atopic dermatitis by enabling the phosphatase PP4C to inhibit the T cell signaling mediator CARD11.
Loh JT; Teo JKH; Kannan S; Verma CS; Andiappan AK; Lim HH; Lam KP
Sci Signal; 2023 Oct; 16(809):eadg5171. PubMed ID: 37906628
[TBL] [Abstract][Full Text] [Related]
33. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
34. Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease.
Dorjbal B; Stinson JR; Ma CA; Weinreich MA; Miraghazadeh B; Hartberger JM; Frey-Jakobs S; Weidinger S; Moebus L; Franke A; Schäffer AA; Bulashevska A; Fuchs S; Ehl S; Limaye S; Arkwright PD; Briggs TA; Langley C; Bethune C; Whyte AF; Alachkar H; Nejentsev S; DiMaggio T; Nelson CG; Stone KD; Nason M; Brittain EH; Oler AJ; Veltri DP; Leahy TR; Conlon N; Poli MC; Borzutzky A; Cohen JI; Davis J; Lambert MP; Romberg N; Sullivan KE; Paris K; Freeman AF; Lucas L; Chandrakasan S; Savic S; Hambleton S; Patel SY; Jordan MB; Theos A; Lebensburger J; Atkinson TP; Torgerson TR; Chinn IK; Milner JD; Grimbacher B; Cook MC; Snow AL
J Allergy Clin Immunol; 2019 Apr; 143(4):1482-1495. PubMed ID: 30170123
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.
Worm M; Simpson EL; Thaçi D; Bissonnette R; Lacour JP; Beissert S; Kawashima M; Ferrándiz C; Smith CH; Beck LA; Chan KC; Chen Z; Akinlade B; Hultsch T; Staudinger H; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Ardeleanu M
JAMA Dermatol; 2020 Feb; 156(2):131-143. PubMed ID: 31876900
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
37. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
[TBL] [Abstract][Full Text] [Related]
38. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of a case series of adult patients with severe atopic dermatitis treated with dupilumab in Argentina].
Máspero J; Angles MV; Ardusso L; Brancciforte M; Castro C; Cruz Iturrieta C; Chouela E; De Gennaro MS; Fernández Bussy R; Galimberti ML; Galimberti RL; Gattolin G; Luna PC; Magariños G; Marini MG; Maskin M; Plafnik R; Raimondo N; Russo JP; Sevinsky L; Stringa MF
Rev Fac Cien Med Univ Nac Cordoba; 2020 Jun; 77(2):94-99. PubMed ID: 32558511
[TBL] [Abstract][Full Text] [Related]
40. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
